These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9490681)

  • 21. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
    Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
    Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
    Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
    Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
    Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML
    Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue-type plasminogen activator and its substrate Glu-plasminogen share common binding sites in limited plasmin-digested fibrin.
    de Vries C; Veerman H; Koornneef E; Pannekoek H
    J Biol Chem; 1990 Aug; 265(23):13547-52. PubMed ID: 2143185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I.
    Harpel PC; Chang TS; Verderber E
    J Biol Chem; 1985 Apr; 260(7):4432-40. PubMed ID: 3156857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
    Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
    Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
    Boutaud A; Castellino FJ
    Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence that the conformation of unliganded human plasminogen is maintained via an intramolecular interaction between the lysine-binding site of kringle 5 and the N-terminal peptide.
    Cockell CS; Marshall JM; Dawson KM; Cederholm-Williams SA; Ponting CP
    Biochem J; 1998 Jul; 333 ( Pt 1)(Pt 1):99-105. PubMed ID: 9639568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of nonproteolytic active site formation in plasminogen.
    Gladysheva IP; Sazonova IY; Houng A; Hedstrom L; Reed GL
    Biochemistry; 2007 Jul; 46(30):8879-87. PubMed ID: 17616171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue-type plasminogen activator (tPA) interacts with urokinase-type plasminogen activator (uPA) via tPA's lysine binding site. An explanation of the poor fibrin affinity of recombinant tPA/uPA chimeric molecules.
    Novokhatny V; Medved L; Lijnen HR; Ingham K
    J Biol Chem; 1995 Apr; 270(15):8680-5. PubMed ID: 7721771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory effect of angiostatins on activity of the plasminogen/plasminogen activator system.
    Aisina RB; Mukhametova LI; Gulin DA; Levashov MY; Prisyazhnaya NV; Gershkovich KB; Varfolomeyev SD
    Biochemistry (Mosc); 2009 Oct; 74(10):1104-13. PubMed ID: 19916923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A battery of monoclonal antibodies that induce unique conformations to evolve cryptic but constitutive functions of plasminogen.
    Madoiwa S; Arai K; Ueda Y; Ishizuka M; Mimuro J; Asakura S; Matsuda M; Sakata Y
    J Biochem; 1997 Feb; 121(2):278-87. PubMed ID: 9089401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrinolytic cross-talk: a new mechanism for plasmin formation.
    Dejouvencel T; Doeuvre L; Lacroix R; Plawinski L; Dignat-George F; Lijnen HR; Anglés-Cano E
    Blood; 2010 Mar; 115(10):2048-56. PubMed ID: 19996088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N; Iwamoto M; Abiko Y
    Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
    Hajjar KA; Hamel NM
    J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin.
    Sorrell AM; Shand JH; Tonner E; Gamberoni M; Accorsi PA; Beattie J; Allan GJ; Flint DJ
    J Biol Chem; 2006 Apr; 281(16):10883-9. PubMed ID: 16505491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrinolysis: the key to new pathogenetic mechanisms.
    Zorio E; Gilabert-Estellés J; España F; Ramón LA; Cosín R; Estellés A
    Curr Med Chem; 2008; 15(9):923-9. PubMed ID: 18473800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conversion of Glu-plasminogen to Lys-plasminogen is necessary for optimal stimulation of plasminogen activation on the endothelial cell surface.
    Gong Y; Kim SO; Felez J; Grella DK; Castellino FJ; Miles LA
    J Biol Chem; 2001 Jun; 276(22):19078-83. PubMed ID: 11264290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decoy plasminogen receptor containing a selective Kunitz-inhibitory domain.
    Kumar Y; Vadivel K; Schmidt AE; Ogueli GI; Ponnuraj SM; Rannulu N; Loo JA; Bajaj MS; Bajaj SP
    Biochemistry; 2014 Jan; 53(3):505-17. PubMed ID: 24383758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects.
    Bikfalvi A; Sauzeau C; Moukadiri H; Maclouf J; Busso N; Bryckaert M; Plouet J; Tobelem G
    J Cell Physiol; 1991 Oct; 149(1):50-9. PubMed ID: 1719003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.